Since the introduction of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML),
the management of this disease has completely changed. The aim has been first to bring to …

Achievement of complete molecular response in patients with chronic phase chronic
myeloid leukemia has been recognized as an important milestone in therapy cessation and …

Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6
months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical …

Abstract 3784 Background: TKI are standard therapy for patients with CML CP. Imatinib was
first established as frontline therapy and more recently dasatinib and nilotinib have shown …

Targeted therapy for chronic myeloid leukaemia (CML) has allowed for a near‐normal
patient life‐expectancy; however, quality of life and aggravation of existing co‐morbidities …

Tyrosine kinase inhibitors (TKI) have dramatically changed the management and the
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …

Chronic myeloid leukemia (CML) is a model disease of modern precision oncology.
Tyrosine kinase inhibitor (TKI) treatment targeting the pathological BCR-ABL1 protein …

Early molecular response has been associated with clinical outcome in chronic myeloid
leukemia (CML) patients treated with tyrosine kinase inhibitors. The BCR-ABL1 transcript …

CML patients who obtain a complete cytogenetic response (CCgR) may harbor different
degrees of molecular disease, which are associated with different progression-free survival …

Background In this study we aimed to evaluate appropriate time points for mutation analysis
of chronic myeloid leukemia. Patients and Methods In total, 961 blood samples obtained …